MX2012004709A - Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r. - Google Patents
Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.Info
- Publication number
- MX2012004709A MX2012004709A MX2012004709A MX2012004709A MX2012004709A MX 2012004709 A MX2012004709 A MX 2012004709A MX 2012004709 A MX2012004709 A MX 2012004709A MX 2012004709 A MX2012004709 A MX 2012004709A MX 2012004709 A MX2012004709 A MX 2012004709A
- Authority
- MX
- Mexico
- Prior art keywords
- ddr1
- ddr2
- bcr
- pdgf
- pathological conditions
- Prior art date
Links
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 230000001575 pathological effect Effects 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 101100498819 Caenorhabditis elegans ddr-1 gene Proteins 0.000 title 1
- 102100036723 Discoidin domain-containing receptor 2 Human genes 0.000 abstract 2
- 101710127786 Discoidin domain-containing receptor 2 Proteins 0.000 abstract 2
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 abstract 2
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 abstract 2
- 108091008606 PDGF receptors Proteins 0.000 abstract 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un régimen para la administración de una pirimidil-amino-benzamida de la fórmula I como se define en la presente, para el tratamiento de los trastornos proliferativos, en particular tumores sólidos y líquidos, y otras condiciones patológicas mediadas por la actividad de cinasa de la oncoproteína Bcr-Abl, del receptor de cinasa de tirosina transmembrana celular c-Kit, del DDR1 (receptor de dominio de discoidina 1), del DDR2 (receptor de dominio de discoidina 2), o del PDGF-R (receptor del factor de crecimiento derivado de plaquetas).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25432309P | 2009-10-23 | 2009-10-23 | |
| PCT/US2010/053459 WO2011050120A1 (en) | 2009-10-23 | 2010-10-21 | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012004709A true MX2012004709A (es) | 2012-05-23 |
Family
ID=43222136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004709A MX2012004709A (es) | 2009-10-23 | 2010-10-21 | Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r. |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20120202836A1 (es) |
| EP (1) | EP2490690A1 (es) |
| JP (1) | JP5948246B2 (es) |
| KR (2) | KR101853596B1 (es) |
| CN (1) | CN102647986A (es) |
| AU (3) | AU2010310705A1 (es) |
| BR (1) | BR112012009094A8 (es) |
| CA (1) | CA2777019A1 (es) |
| CL (1) | CL2012001012A1 (es) |
| IL (1) | IL219109A (es) |
| MA (1) | MA33666B1 (es) |
| MX (1) | MX2012004709A (es) |
| NZ (1) | NZ599217A (es) |
| PH (1) | PH12012500797A1 (es) |
| RU (1) | RU2012120901A (es) |
| TN (1) | TN2012000150A1 (es) |
| TW (1) | TWI592157B (es) |
| WO (1) | WO2011050120A1 (es) |
| ZA (1) | ZA201202413B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2776130A1 (en) | 2011-11-07 | 2014-09-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
| TW201348187A (zh) * | 2012-04-24 | 2013-12-01 | Chugai Pharmaceutical Co Ltd | 苯甲醯胺衍生物 |
| WO2013161853A1 (ja) * | 2012-04-24 | 2013-10-31 | 中外製薬株式会社 | キナゾリンジオン誘導体 |
| CA3134922A1 (en) | 2012-05-02 | 2013-11-07 | Georgetown University | Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors |
| EP4129286A1 (en) | 2012-12-27 | 2023-02-08 | Quest Diagnostics Investments Incorporated | Ddr2 mutations as targetable features of melanoma or basal cell carcinoma |
| CN103965195B (zh) * | 2013-02-01 | 2016-09-28 | 中国科学院广州生物医药与健康研究院 | 用于盘状结构域受体小分子抑制剂的化合物及其应用 |
| US10857090B2 (en) * | 2013-07-05 | 2020-12-08 | Stellar Biome Inc. | Oral compositions |
| TW201605805A (zh) | 2013-10-23 | 2016-02-16 | Chugai Pharmaceutical Co Ltd | 喹唑啉酮及異喹啉酮衍生物 |
| AU2016316223A1 (en) * | 2015-08-31 | 2018-02-22 | Toray Industries, Inc. | Urea derivative and use therefor |
| AU2019385480B2 (en) | 2018-11-20 | 2025-04-24 | Georgetown University | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders |
| WO2020207570A1 (en) * | 2019-04-09 | 2020-10-15 | Rottapharm Biotech S.R.L. | Phenazines as inhibitors of discoidin domain receptors 2 (ddr2) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002963A1 (ja) | 2002-06-28 | 2004-01-08 | Nippon Shinyaku Co., Ltd. | アミド誘導体及び医薬 |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| CA2629132C (en) * | 2005-12-06 | 2014-05-27 | Novartis Ag | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| US7729791B2 (en) * | 2006-09-11 | 2010-06-01 | Apple Inc. | Portable media playback device including user interface event passthrough to non-media-playback processing |
| EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| SI2187967T1 (sl) * | 2007-08-16 | 2013-07-31 | Irm Llc | Postopki in sestavki za zdravljenje raka |
-
2010
- 2010-10-21 MX MX2012004709A patent/MX2012004709A/es unknown
- 2010-10-21 NZ NZ599217A patent/NZ599217A/en not_active IP Right Cessation
- 2010-10-21 RU RU2012120901/04A patent/RU2012120901A/ru not_active Application Discontinuation
- 2010-10-21 CN CN2010800461900A patent/CN102647986A/zh active Pending
- 2010-10-21 BR BR112012009094A patent/BR112012009094A8/pt not_active IP Right Cessation
- 2010-10-21 KR KR1020177001075A patent/KR101853596B1/ko not_active Expired - Fee Related
- 2010-10-21 JP JP2012535351A patent/JP5948246B2/ja not_active Expired - Fee Related
- 2010-10-21 KR KR1020127010179A patent/KR20120099650A/ko not_active Ceased
- 2010-10-21 PH PH1/2012/500797A patent/PH12012500797A1/en unknown
- 2010-10-21 CA CA2777019A patent/CA2777019A1/en not_active Abandoned
- 2010-10-21 US US13/501,274 patent/US20120202836A1/en not_active Abandoned
- 2010-10-21 WO PCT/US2010/053459 patent/WO2011050120A1/en not_active Ceased
- 2010-10-21 AU AU2010310705A patent/AU2010310705A1/en not_active Abandoned
- 2010-10-21 EP EP10773472A patent/EP2490690A1/en not_active Withdrawn
- 2010-10-22 TW TW099136217A patent/TWI592157B/zh not_active IP Right Cessation
-
2012
- 2012-04-02 TN TNP2012000150A patent/TN2012000150A1/en unknown
- 2012-04-03 ZA ZA2012/02413A patent/ZA201202413B/en unknown
- 2012-04-05 IL IL219109A patent/IL219109A/en not_active IP Right Cessation
- 2012-04-10 MA MA34769A patent/MA33666B1/fr unknown
- 2012-04-20 CL CL2012001012A patent/CL2012001012A1/es unknown
-
2014
- 2014-04-29 US US14/264,357 patent/US20140350037A1/en not_active Abandoned
- 2014-05-30 AU AU2014202963A patent/AU2014202963A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/797,716 patent/US20150313900A1/en not_active Abandoned
-
2016
- 2016-08-18 AU AU2016216636A patent/AU2016216636B2/en not_active Expired - Fee Related
-
2017
- 2017-02-06 US US15/425,417 patent/US20170143716A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012120901A (ru) | 2013-12-10 |
| IL219109A0 (en) | 2012-06-28 |
| AU2016216636A1 (en) | 2016-09-01 |
| IL219109A (en) | 2017-12-31 |
| EP2490690A1 (en) | 2012-08-29 |
| NZ599217A (en) | 2014-05-30 |
| ZA201202413B (en) | 2013-03-27 |
| TN2012000150A1 (en) | 2013-12-12 |
| US20170143716A1 (en) | 2017-05-25 |
| TWI592157B (zh) | 2017-07-21 |
| TW201127383A (en) | 2011-08-16 |
| WO2011050120A1 (en) | 2011-04-28 |
| MA33666B1 (fr) | 2012-10-01 |
| AU2016216636B2 (en) | 2018-06-07 |
| KR20120099650A (ko) | 2012-09-11 |
| KR101853596B1 (ko) | 2018-04-30 |
| JP2013508393A (ja) | 2013-03-07 |
| CN102647986A (zh) | 2012-08-22 |
| US20150313900A1 (en) | 2015-11-05 |
| AU2014202963A1 (en) | 2014-06-19 |
| US20120202836A1 (en) | 2012-08-09 |
| US20140350037A1 (en) | 2014-11-27 |
| BR112012009094A2 (pt) | 2016-05-03 |
| AU2010310705A1 (en) | 2012-04-19 |
| BR112012009094A8 (pt) | 2017-10-10 |
| PH12012500797A1 (en) | 2012-11-26 |
| KR20170007868A (ko) | 2017-01-20 |
| CL2012001012A1 (es) | 2012-10-26 |
| CA2777019A1 (en) | 2011-04-28 |
| JP5948246B2 (ja) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012004709A (es) | Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r. | |
| CO6551690A2 (es) | Método para el tratamiento de transtornos proliferativos y otras condiciones patológicas mediadas por la actividad de cinasa de bcr -abl, c-kit,ddr1, ddr2 o pdgf-r | |
| EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| CO6170360A2 (es) | Derivados de pirimidinil - piridazinona | |
| MX389376B (es) | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr). | |
| UA112795C2 (uk) | Біциклічні піразинонові похідні | |
| BR112013002220A2 (pt) | derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo | |
| NI201100052A (es) | Derivados de picolinamida como inhibidores de cinasa. | |
| CR20110029A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina | |
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| ECSP12011716A (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| UY32125A (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| EA201401212A1 (ru) | Производные пирролотриазинона | |
| PH12014500794A1 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| EA201590820A1 (ru) | Производные 4-карбоксамидоизоиндолинона в качестве селективных ингибиторов parp-1 | |
| MX376059B (es) | Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk). | |
| EA201491026A1 (ru) | Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1 | |
| EA201101042A1 (ru) | Производные бензотиазолона | |
| EA201101038A1 (ru) | Производные пиридазинона | |
| CY1117519T1 (el) | Μεθοδος θεραπειας πολλαπλασιαστικων διαταραχων και αλλων παθολογικων καταστασεων που προκαλουνται απο bcr-abl, c-kit, ddr1, ddr2 ή pdgf-r δραστηριοτητα κινασης | |
| UY33553A (es) | Heteroarilos y usos de los mismos | |
| CU23997B1 (es) | Derivados de picolinamida como inhibidores de cinasa | |
| TN2011000070A1 (en) | Picolinamide derivatives as kinase inhibitors |